Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Percheron Therapeutics.
RELATED STOCKHEAD STORIES
Health & Biotech
ASX Health Stocks: Emyria surges another 10pc; cannabis play Vitura delivers record profit
Health & Biotech
Check Up: The FDA refuses to give CBD a green light, but market doesn’t seem to care
Health & Biotech
ScoPo’s Powerplays: ASX health stocks dancing to a positive tune
Health & Biotech
ASX Health Stocks: EMV jumps 7pc after delivering portable brain scanner; Firebrick gets Aussie patent
Health & Biotech
Phase III Trials: These ASX health stocks are on the pivotal home stretch
Health & Biotech
ASX Health Stocks: Antisense commences trial dosing, Shine lawyers deliver historic $300m settlement
Health & Biotech
Check Up: As the pandemic winds down, what’s happening with Covid focused biotechs?
Health & Biotech
ASX Health Stocks: Big announcements as Invex and Antisense jump over 20pc this morning
Experts
ScoPo’s Powerplays: ASX health stocks up for second week, investors get reason to smile
Health & Biotech
ScoPo’s Powerplays: ASX health stocks show signs of jittery recovery
Health & Biotech
ASX Health Stocks: Antisense says ATL1102 could be effective in rare genetic muscle disease
Health & Biotech
ASX Health Stocks: NeuroScientific gains on study news; FDA report gives Auscann a boost
Health & Biotech
ASX Health Stocks: Virtus is being pursued as Bionomics prepares for dual Nasdaq listing
Health & Biotech
ASX Health Stocks: Aussie biotechs Argenica and Antisense take major steps in the US
Health & Biotech
ASX Health Stocks: Visioneering jumps 13pc on contact lenses launch, Sigma drops bid for API
Health & Biotech
Check Up: Fundie says ‘buy the dip’ as biotech loses shine amid pandemic rebound
Health & Biotech